

**Statement under Regulation 13(3) of SEBI (Listing Obligation  
and Disclosure Requirements) Regulations, 2015, for the  
Quarter ended on 31<sup>st</sup> December, 2016**

Particulars	31/12/2016
<b>Investors' Complaints</b>	
Pending at the beginning of the quarter	NIL
Received during the quarter	1
Disposed of during the quarter	1
Remaining unsolved at the end of the quarter	NIL

For Jenburkt Pharmaceuticals Limited



Ashish R. Shah

Company Secretary & Complaints Officer.